N/A
Completed N=560
Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
Source: ClinicalTrials.gov NCT03219723 ↗Enrolled (actual)
560
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcomePrimary: Percentage of Participants Who Had One or More Adverse Drug Reactions — 3.09 Percentage of Participants
Summary
The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Who Had One or More Adverse Drug Reactions |
3.09 | — |
| SECONDARY H. Pylori Eradication Rate |
91.24; 95.45 | — |
Eligibility Criteria
Inclusion Criteria
- Participants receiving H. pylori eradication treatment for the first time
- Participants for whom H. pylori eradication with Takecab tablets or proton pump inhibitor + amoxicillin + clarithromycin was found unsuccessful and who will receive eradication treatment with amoxicillin and metronidazole
Exclusion Criteria
- Participants with previous history of hypersensitivity to ingredients in Takecab tablets
- Participants taking atazanavir sulfate or rilpivirine hydrochloride
Data sourced from ClinicalTrials.gov (NCT03219723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.